Expert Consensus on Clinical Application of Qidong Yixin Oral Liquid
10.13422/j.cnki.syfjx.20252095
- VernacularTitle:芪冬颐心口服液临床应用专家共识
- Author:
Changkuan FU
1
;
Xiaochang MA
2
;
Mingjun ZHU
3
;
Yue DENG
4
;
Hongxu LIU
5
;
Mingxue ZHANG
6
;
Ying CHEN
4
;
Yan ZHOU
7
;
Ling ZHANG
8
;
Jianhua FU
2
;
Wei YANG
4
;
Yu'er HU
1
;
Ming CHEN
1
;
Yanming XIE
1
;
Yuanyuan LI
1
Author Information
1. Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences，Beijing 100700，China
2. Xiyuan Hospital of China Academy of Chinese Medical Sciences，Beijing 100091，China
3. The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China
4. The Affiliated Hospital to Changchun University of Chinese Medicine，Changchun 130021，China
5. Beijing Hospital of Traditional Chinese Medicine（TCM），Capital Medical University，Beijing 100010，China
6. Affiliated Hospital of Liaoning University of TCM，Shenyang 110000，China
7. The First Hospital of Jilin University，Changchun 130021，China
8. School of Public Health，Capital Medical University，Beijing 100069，China
- Publication Type:Journal Article
- Keywords:
Qidong Yixin oral liquid;
expert consensus;
evidence evaluation;
recommendation opinion;
consensus suggestion
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2026;32(4):147-158
- CountryChina
- Language:Chinese
-
Abstract:
The prescription of Qidong Yixin oral liquid is derived from the experience of national medical master Ren Jixue in treating viral myocarditis （VMC）. It has the functions of tonifying Qi， nourishing the heart，calming the mind， and relieving palpitations. It is used to treat VMC and angina pectoris of coronary heart disease caused by deficiency of both Qi and Yin. However，the understanding of its efficacy evidence， advantageous aspects， dosage and administration， and medication safety remains insufficient in clinical practice. Therefore，the development of the Expert Consensus on the Clinical Application of Qidong Yixin Oral Liquid （hereinafter referred to as consensus） was initiated. Consensus strictly followed the process and methods of the expert consensus on the clinical application of Chinese patent medicines of the China Association of Chinese Medicine，successively completing multiple tasks such as the consensus project initiation，determination of clinical problems，evidence search and evaluation，formation of recommendation opinions and consensus suggestions，solicitation of opinions，peer review， submission for review and release， and so on. Consensus formed a total of 10 recommendation opinions and 12 consensus suggestions，clarifying the clinical positioning，efficacy advantages，syndrome differentiation，dosage and administration，combination therapy，timing of medication，adverse reactions，contraindications， and precautions of Qidong Yixin oral liquid，indicating that it has good clinical advantages and safety in the treatment of VMC and angina pectoris of coronary heart disease，providing norms and references for physicians to safely and rationally apply Qidong Yixin oral liquid. Consensus was reviewed and approved for release by the Standardization Office of the China Association of Chinese Medicine on December 23， 2024. Standard number：GSCACM-376-2024.
